Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus YAELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus YAELA.
CONEXXENCE vs YAELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Yaela is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity, contributing to contraceptive efficacy and reducing fluid retention.
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
The standard adult dose of Yaela (ethinyl estradiol/levonorgestrel) for oral contraception is 1 tablet (containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel) taken orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Terminal elimination half-life is 12 ± 3 hours (range 8-16 hours) in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal excretion of unchanged drug accounts for approximately 70% of the administered dose; biliary/fecal excretion accounts for 30%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive